Delving into the Latest Updates on Dulaglutide with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Dulaglutide (Genetical Recombination), Dulaglutide (genetical recombination) (JAN), Dulaglutide (USAN/INN)

+ [8]

Target

GLP-1R

Action

agonists

Mechanism

GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Diabetes Mellitus, Type 2Hypoglycemia

Inactive Indication

Cardiovascular DiseasesChronic Kidney DiseasesDiabetes Mellitus, Insulin-Dependent, 3+ [7]

Originator Organization

Eli Lilly & Co.

Active Organization

Eli Lilly Nederland BV

Eli Lilly & Co.Eli Lilly Australia Pty Ltd.

Inactive Organization

Lilly Asia Shanghai Representative Office

Drug Highest PhaseApproved

First Approval Date

United States (18 Sep 2014),

Diabetes Mellitus, Type 2

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Sequence Code 51033

Source: *****

The goal of this clinical trial is to assess the efficacy of a pharmacogenetics-guided treatment, compared to standard optimized treatment, in patients with inadequately controlled type 2 diabetes. The main questions it aims to answer are:
* Is the disease better controlled when the treatment prescribed is based on the participant's pharmacogenetic profile?
* What medical problems do participants experience while taking the treatment?
Participants will:
* Take the treatment described according to the Summary of Product Characteristics (SmPC).
* Visit the clinic once every 12 weeks for checkups and tests.
* Keep a diary of their symptoms to inform the Investigator.

Start Date01 Apr 2025

Sponsor / Collaborator-

ChiCTR2500098958

/ SuspendedNot ApplicableIIT

Targeted GLP-1R PET imaging in the clinical application of endogenous hyperinsulinemia

Start Date18 Mar 2025

Sponsor / Collaborator-

ACTRN12624001245583

/ Not yet recruitingEarly Phase 1IIT

SUBDUE-3: A Phase 0 study of SUB-urothelial DUrvalumab-Zirconium to investigate local and systemic distribution of Durvalumab when injected in the sub-urothelium of adult subjects with muscle invasive bladder cancer or high-risk non-muscle invasive bladder cancer

Start Date10 Feb 2025

Sponsor / Collaborator-

100 Clinical Results associated with Dulaglutide

Login to view more data

100 Translational Medicine associated with Dulaglutide

Login to view more data

100 Patents (Medical) associated with Dulaglutide

Login to view more data

1,802

Literatures (Medical) associated with Dulaglutide

01 Dec 2025·Current Neurology and Neuroscience Reports

Special Considerations in the Treatment of Idiopathic Intracranial Hypertension

Review

Author: Friedman, Deborah I

PURPOSE OF REVIEW:

To review the management of Idiopathic Intracranial Hypertension (IIH) with co-existing conditions affecting therapy: obesity, sulfa allergy, nephrolithiasis, and pregnancy.

RECENT FINDINGS:

The IIH-WT trial showed that bariatric surgery is currently the most effective method for obese patients with IIH to lose weight, leading to normalization of CSF pressure in many cases. Allergy to sulfonamide antibiotics does not preclude the use of acetazolamide; rather, penicillin allergy or multiple drug allergies are the strongest predictor of a hypersensitivity reaction. Carbonic anhydrase inhibitors should be avoided in individuals with a personal history of nephrolithiasis; the risk of renal stones increases with concomitant use of other medications with the potential for nephrolithiasis. Glucagon-like peptide-1 receptor antagonists (GLP-1RA) are promising non-surgical weight loss options although preliminary studies have not demonstrated considerable impact on papilledema, headache or vision. Women with IIH have high rates of pregnancy complications partly related to obesity. Recommendations for weight gain or loss during gestation are controversial. Recent studies show better outcomes in obese women who maintain or lose weight while pregnant including gestational diabetes, pre-eclampsia and emergency caesarian section. Progress continues in the search for the cause and best treatments for IIH. Larger multicenter trials of GLP-1RA are needed to determine their efficacy.

01 Jun 2025·AMERICAN JOURNAL OF OPHTHALMOLOGY

The Effect of Semaglutide and GLP-1 RAs on Risk of Nonarteritic Anterior Ischemic Optic Neuropathy

Article

Author: Talcott, Katherine E ; Allan, Kevin C ; Nahlawi, Raya ; Kaelber, David C ; Singh, Rishi P ; Shaia, Jacqueline K ; Abbass, Nadia J

PURPOSE:

The association between GLP-1 receptor agonists (GLP-1RA) and nonarteritic anterior ischemic optic neuropathy (NAION) remains unclear. Given the debilitating sequelae of NAION and rapid increase of GLP-1RA use, further research is essential to investigate this potential relationship. This study seeks to determine the risk of NAION and ischemic optic neuropathy (ION) in patients prescribed GLP-1RAs.

DESIGN:

Retrospective matched cohort study.

SETTING:

TriNetX United States collaborative network.

PARTICIPANTS:

Patients ≥12 years old with type 2 diabetes (T2DM) and considered overweight or obese (high BMI), with at least one ophthalmology or neurology visit. Among T2DM patients, approximately 120,000 patients with a semaglutide prescription and 220,000 prescribed any GLP-1RA were compared to matched T2DM controls. Among high BMI patients, approximately 58,000 on semaglutide and 66,000 on any GLP-1RA were compared to matched controls.

METHODS:

Patients prescribed semaglutide or any GLP-1RA were compared with those on non-GLP-1RA medications. Populations were propensity matched (1:1) on various demographic and risk factors to balance baseline cohorts.

MAIN OUTCOMES AND MEASURES:

Cumulative incidence and risk of NAION and ION. Risk ratios (RR) with 95% confidence intervals (CI) were reported, with significance defined as CI <0.9 or > 1.1.

RESULTS:

In T2DM patients prescribed semaglutide, the risk of NAION (RR = 0.7, 95% CI: 0.523-0.937) and ION (RR = 0.788, 95% CI: 0.609-1.102) after 5 years was not significantly increased compared to matched T2DM controls. Similarly, T2DM patients on any GLP-1RA demonstrated no significant difference in the risk of NAION (RR = 0.887, 95% CI: 0.735-1.071) or ION (RR = 0.969, 95% CI: 0.813-1.154) compared to controls. Furthermore, no increased risk of either outcome was found in the high BMI groups prescribed semaglutide or any GLP-1RA. The cumulative 5-year risk of NAION and ION in T2DM patients on semaglutide was 0.065% and 0.08%, respectively. In those with high BMI prescribed semaglutide, the risk of NAION and ION after 2 years was 0.038% and 0.404%, respectively.

CONCLUSIONS:

There was no significant increase in risk of NAION or ION in patients taking semaglutide or GLP-1RAs compared to T2DM or high BMI controls.

01 May 2025·PHARMACOLOGY & THERAPEUTICS

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

Review

Author: Arredouani, Abdelilah

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as groundbreaking therapeutic agents in managing a spectrum of metabolic disorders, demonstrating remarkable efficacy across multiple organ systems and disease states. These compounds are not only well-established in the treatment of type 2 diabetes (T2D) and obesity-conditions for which they have received widespread approval-but also exhibit promising potential in addressing cardiovascular disease (CVD) and Metabolic dysfunction-associated steatotic liver disease (MASLD). Recent investigations have begun to illuminate the utility of GLP-1RAs in the management of type 1 diabetes (T1D), as well as neurodegenerative disorders such as Alzheimer's and Parkinson's disease and various behavioral disorders. A plethora of clinical trials have consistently validated the capacity of GLP-1RAs to improve glycemic control, promote weight loss, and mitigate cardiovascular risk factors in individuals with T2D and obesity. While their application in T1D remains limited due to safety concerns-particularly regarding the risks of hypoglycemia and hyperglycemic ketoacidosis-emerging data suggest that GLP-1RAs may offer hepatoprotective benefits, potentially reducing liver fat content and decelerating the progression of MASLD. The neuroprotective attributes of GLP-1 RAs have garnered significant interest, with research indicating their potential to alleviate cognitive decline associated with neurodegenerative diseases. Furthermore, preliminary findings highlight the role of GLP-1 RAs in addressing behavioral disorders, emphasizing their extensive therapeutic promise. This comprehensive review synthesizes the current evidence supporting the diverse therapeutic applications of GLP-1RAs, positioning them as "magic drug" therapies for metabolic and neurological disorders. As ongoing research continues to explore innovative applications and combinations of GLP-1RAs, the landscape of disease management in metabolic and neurological contexts is poised for transformative advancements. This review will also critically assess safety considerations and underscore the need for personalized treatment strategies to optimize patient outcomes in these complex and often comorbid conditions.

427

News (Medical) associated with Dulaglutide

18 Mar 2025

·www.drugs.com

GLP-1 RA Use Tied to Better Kidney Transplant Outcomes in Patients With Diabetes

TUESDAY, March 18, 2025 -- Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes , according to a study published online March 5 in The Lancet Diabetes & Endocrinology . Babak J. Orandi, M.D., Ph.D., from New York University in New York City, and colleagues examined the real-world safety and effectiveness of GLP-1 RA use in kidney transplant recipients with diabetes. The analysis included 18,016 kidney transplant recipients with diabetes (2013 through 2020) covered by Medicare, of whom 10.9 percent had at least one GLP-1 RA prescription filled posttransplant. The researchers found that the five-year unadjusted cumulative incidence of death-censored graft loss from a cohort matched on survival time before GLP-1 RA initiation was 6.0 percent for GLP-1 RA users and 10.7 percent for nonusers. Based on a cohort matched on survival time before GLP-1 RA initiation, the five-year unadjusted cumulative incidence for mortality was 17.0 percent for GLP-1 RA users and 25.8 percent for nonusers. Use of GLP-1 RAs was associated with lower incidence of death-censored graft loss (adjusted subhazard ratio, 0.51) and lower mortality (adjusted hazard ratio, 0.69). GLP-1 RA use was not associated with safety end points, with the exception of diabetic retinopathy (adjusted hazard ratio, 1.49). "Our study results are the strongest evidence to date that GLP-1 agonist drugs are largely safe and effective tools for addressing type 2 diabetes in kidney transplant recipients," Orandi said in a statement. Several authors disclosed ties to the pharmaceutical industry.

Clinical Result

11 Mar 2025

·www.drugs.com

AAOS: Stopping GLP-1 RAs 14 Days Before Surgery Can Minimize Complications

TUESDAY, March 11, 2025 -- Stopping glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment 14 days before total joint arthroplasty can minimize risks for complications, according to a study presented at the annual meeting of the American Academy of Orthopaedic Surgeons, held from March 10 to 14 in San Diego. Shivan N. Chokshi, M.D., from the University of Tennessee Campbell Clinic in Memphis, and colleagues examined the association between the time of last Ozempic dose and anesthesia complications in patients who underwent total hip or knee arthroplasty from January 2018 to January 2023. Ozempic users were classified based on when they stopped medication before surgery (482, 591, 680, 758, 777, and 706 at 30, 14, seven, five, three, and one day before surgery, respectively; 170 patients continued use through surgery); the control group included 206,005 patients without prior Ozempic use. The researchers found that stopping Ozempic five days, three days, and one day prior to surgery was an independent risk factor for delayed emergence from anesthesia (odds ratios, 1.59, 1.84, and 2.23, respectively). Stopping seven days prior was a risk factor for aspiration pneumonitis (odds ratio, 1.29), with higher risks seen for stopping five days and one day prior (odds ratios, 2.74 and 2.74, respectively). Last Ozempic dose at seven days prior to surgery was identified as an independent risk factor for conversion to intubation in multivariate logistic regression (odds ratio, 1.39). Last Ozempic dose at five days, three days, and one day prior were independent risk factors for conversion to intubation (odds ratios, 2.09, 4.68, and 6.37, respectively). Patients who continued Ozempic through surgery had the highest risk for complications. "To minimize risks of delayed emergence from anesthesia, aspiration, aspiration pneumonitis, and conversion to intubation, ceasing GLP-1 RA 14 days before surgery is optimal," the authors write. Press Release More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

10 Mar 2025

·www.drugs.com

Risk for Specific Hematologic Cancers Down With GLP-1 Receptor Agonist Use in T2DM

MONDAY, March 10, 2025 -- For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use, according to a research letter published online March 6 in JAMA Network Open . Omer S. Ashruf, from Northeast Ohio Medical University in Rootstown, and colleagues conducted a retrospective cohort study to compare the risks for hematologic cancers in patients with T2D treated with a GLP-1 RA versus metformin and insulin. The study included patients with T2D prescribed a GLP-1 RA, insulin, or metformin between April 30, 2005, and Oct. 31, 2023 (51,617; 611,115; and 938,602 patients, respectively). Groups were independently matched using a nearest neighbor greedy matching algorithm; 47,716 patients were included in the GLP-1 RA-insulin analysis and 50,590 were included in the GLP-1 RA-metformin analysis. The researchers found that GLP-1 RA use was associated with significantly lower risks for of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) compared with metformin (hazard ratios, 0.61 and 0.67, respectively). No significant difference was seen in the risk for any other hematologic cancer. GLP-1 RA use was associated with significantly lower risks for myeloid leukemia, lymphoid leukemia, non-Hodgkin lymphoma, MDS, MPN, monoclonal gammopathy, multiple myeloma, and amyloidosis compared with insulin (hazard ratios, 0.39, 0.45, 0.42, 0.19, 0.50, 0.68, 0.49, and 0.52, respectively). GLP-1 RA use was associated with a 54 percent lower risk than that seen with insulin across all hematologic cancers. "The findings of this cohort study suggest that GLP-1 RAs are associated with reduced risk of developing several hematologic cancers, particularly MDS and MPN, in patients with T2D," the authors write. One author disclosed ties to Celegene, BMS, and Carobou. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Clinical ResultClinical Study

100 Deals associated with Dulaglutide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D09889	Dulaglutide	A10BJ05	DB09045

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	United States	Eli Lilly & Co.	18 Sep 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoglycemia	Phase 3	Japan	Eli Lilly & Co.	13 Apr 2021
Chronic Kidney Diseases	Phase 3	United States	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Brazil	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Hungary	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Mexico	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Poland	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Romania	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	South Africa	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Spain	Eli Lilly & Co.	01 Jul 2012
Chronic Kidney Diseases	Phase 3	Ukraine	Eli Lilly & Co.	01 Jul 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


Ra-pacific (ESMO_ELCC2025)	Not Applicable	Non-small cell lung cancer stage III PD-L1 positive	42	Durvalumab	cfxmojojev(lwjgmakgtn) = tszjzyzrbe gxrknavktq (cwaacxqppf ) View more	Positive	26 Mar 2025
NCT04862234 (CTgov)	Phase 4	Hyperglycemia	16	Continuous glucose monitor (CGM), blinded+Dulaglutide (Dulaglutide)	xnfhwhgtzq(osekbmpeia) = qxzbrfucvg bthchndhky (sbvqkmpqdl, 19.70) View more	-	25 Mar 2025
NCT04862234 (CTgov)	Phase 4	Hyperglycemia	16	Continuous glucose monitor (CGM), blinded (Placebo)	xnfhwhgtzq(osekbmpeia) = fukpsbkmky bthchndhky (sbvqkmpqdl, 27.26) View more	-	25 Mar 2025
NCT05659537 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	212	Dulaglutide	pxlzrbubvg = uezjzkxncn yifufzjgvz (zihcswzqvn, gybnrjkrvo - siphbzvykm) View more	-	25 Mar 2025
NCT03204396 (Pubmed \| Eur J Prev Cardiol)	Phase 2	Smoking Cessation	255	Dulaglutide 1.5mg	ktbdjorzob(laqprvvsji) = systolic blood pressure was stable over the period of 52 weeks after smoking cessation qtfyiwsswi (bceodsfzhg )	-	03 Mar 2025
HIMALAYA (ASCO_GI2025)	Not Applicable	-	108	Durvalumab + Tremelimumab	kzfkzfjdek(rptuadtjrz) = maswhluxcb uptedsnupv (yzrylpmiof, 27.5 - 65.1) View more	Positive	23 Jan 2025
HIMALAYA (ASCO_GI2025)	Not Applicable	-	108	Durvalumab	heuglyjkpk(yffsnimqae) = qglchjeges gjogbpmokl (bfwhubrrgm, 6.0 - 12.1) View more	Positive	23 Jan 2025
TOPAZ-1 (ASCO_GI2025)	Not Applicable	Advanced biliary tract cancer	1,099	Durvalumab plus chemotherapy	xzjyftbpjq(kkijqccgyd) = qykodyxaxx bwsckqjvqy (biywaytobx )	Positive	23 Jan 2025
TOPAZ-1 (ASCO_GI2025)	Not Applicable	Advanced biliary tract cancer	1,099	Chemotherapy only	xzjyftbpjq(kkijqccgyd) = bootqdoxrk bwsckqjvqy (biywaytobx )	Positive	23 Jan 2025
ACTRN12623000223639 (ASCO_GI2025)	Not Applicable	Advanced Pancreatic Ductal Adenocarcinoma	30	Gemcitabine + Nab-paclitaxel + LSTA-1 + Durvalumab	umxeyddvnv(nmxgythpgn) = xtsnkbuhbi odlrrbptrl (hvojcymxit )	Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer First line	-	Durvalumab + Lenvatinib + Gemcitabine-based chemotherapy	ykpxhusdlw(jdnarqsbff) = All patients experienced adverse events (AEs), addition of lenvatinib does not increase the risk of AEs raqymfgagl (twsbkjowhs )	Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer First line	-	Durvalumab + Gemcitabine-based chemotherapy		Positive	23 Jan 2025
ASCO_GI2025	Not Applicable	Advanced biliary tract cancer	50	Durvalumab plus gemcitabine and cisplatin	ukpdqntrcj(lkgpntjpyk) = Most AEs were related to chemotherapy, there were 10% immune related AEs yhxzsqrurs (gertqsnzzd )	Positive	23 Jan 2025

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data